Latest Donor lymphocyte infusion Stories
Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease.
Researchers from Indiana University, the University of Michigan, the Fred Hutchinson Cancer Research Center and the Dana-Farber Cancer Institute have identified and validated a biomarker accessible in blood tests that could be used to predict which stem cell transplant patients are at highest risk for a potentially fatal immune response called graft-versus-host disease.
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments.
HOUSTON, Dec. 21, 2010 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced $3 million in Convertible Note funding.
- An interdisciplinary study of social injustice.